Company Vertex Pharmaceuticals Incorporated
Equities
VRTX
US92532F1003
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
397.5 USD | -0.06% | +0.81% | -2.31% |
Business Summary
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Number of employees: 5,400
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
100.0
%
| 8,931 | 100.0 % | 9,869 | 100.0 % | +10.51% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
61.2
%
| 5,699 | 63.8 % | 6,040 | 61.2 % | +5.98% |
Europe
31.5
%
| 2,706 | 30.3 % | 3,109 | 31.5 % | +14.91% |
Other
7.3
%
| 526 | 5.9 % | 720 | 7.3 % | +36.87% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 51 | 31/01/17 | |
Jeffrey Leiden
CHM | Chairman | 68 | 07/07/09 |
Charles Wagner
DFI | Director of Finance/CFO | 55 | 09/04/19 |
Mike Tirozzi
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/18 |
Carmen Bozic
CTO | Chief Tech/Sci/R&D Officer | 61 | 30/04/19 |
Stuart Arbuckle
COO | Chief Operating Officer | 58 | 03/09/12 |
Mark Bunnage
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/15 |
Edward Atkinson
CTO | Chief Tech/Sci/R&D Officer | 58 | 30/06/20 |
David Altshuler
CTO | Chief Tech/Sci/R&D Officer | 59 | 31/12/14 |
Susie Lisa
IRC | Investor Relations Contact | - | 31/08/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 07/06/17 |
Jeffrey Leiden
CHM | Chairman | 68 | 07/07/09 |
Bruce Sachs
BRD | Director/Board Member | 64 | 31/12/97 |
Terrence Kearney
BRD | Director/Board Member | 69 | 16/05/11 |
Lloyd Carney
BRD | Director/Board Member | 62 | 20/02/19 |
Michel Lagarde
BRD | Director/Board Member | 50 | 04/10/23 |
Sangeeta Bhatia
BRD | Director/Board Member | 55 | 17/06/15 |
Diana McKenzie
BRD | Director/Board Member | 59 | 02/06/20 |
Suketu Upadhyay
BRD | Director/Board Member | 55 | 17/05/22 |
Chief Executive Officer | 51 | 31/01/17 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 258,459,343 | 258,168,408 ( 99.89 %) | 0 | 99.89 % |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B | |
-24.71% | 8.24B |
- Stock Market
- Equities
- VRTX Stock
- Company Vertex Pharmaceuticals Incorporated